Navigation Links
ADVENTRX Added to Russell Microcap Index
Date:6/28/2010

SAN DIEGO, June 28 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company was added to the Russell Microcap® Index on June 25, 2010, when Russell Investments reconstituted its family of U.S. indexes.

"Our addition to this widely recognized index, available only to companies listed on a national exchange, is consistent with our goal of increasing awareness of the ADVENTRX opportunity among the institutional investment community," said Brian M. Culley, Chief Executive Officer of ADVENTRX.   "Membership should facilitate our introduction to potential investors, which may prove beneficial as we approach the important milestone of submitting the Exelbine NDA, which is planned for the fourth quarter of this year."

The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market.  It includes 1,000 of the smallest securities in the small-cap Russell 2000® Index based on a combination of their market cap and current index membership and it includes the next 1,000 securities. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies.  The indexes are reconstituted annually.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.  More information can be found on the Company's web site at www.adventrx.com.  

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties are fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  The leader in ... that Drs. Sam Daher , Manal Ibrahim ... and David Couchat will be the featured microlecture presenters ... upcoming American Association of Orthodontists (AAO) Annual Session, April ... attend the microlectures beginning daily at 11:20 a.m. On ...
(Date:3/29/2017)... Texas , March 29, 2017  Maxor National ... today announced that it has named Leah Bailey ... for all divisions of the company. With ... including the previous 8 years focused on health care, ... During her tenure at Prime, Bailey advised the PBM, ...
(Date:3/29/2017)... 2017  Designers of primary cell wearable medical and ... 50% and extend battery life with the MAX20310 ultra-low ... (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... voltage of just 0.7V for new high-energy density battery ... well as the more common Alkaline battery architecture. With ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
Breaking Medicine News(10 mins):